360 related articles for article (PubMed ID: 37247645)
1. Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
Qu J; Xu J; Liu Y; Hu C; Zhong C; Lv X
Int J Antimicrob Agents; 2023 Aug; 62(2):106872. PubMed ID: 37247645
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
Zhang F; Li P; Zhong J; Ding H; Liao G; Liang C
Front Cell Infect Microbiol; 2024; 14():1404404. PubMed ID: 38779560
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.
Zhuang HH; Chen Y; Hu Q; Long WM; Wu XL; Wang Q; Xu TT; Qu Q; Liu YP; Xiao YW; Qu J
J Infect Public Health; 2023 Jun; 16(6):938-947. PubMed ID: 37087853
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
Zhong H; Zhao XY; Zhang ZL; Gu ZC; Zhang C; Gao Y; Cui M
Int J Antimicrob Agents; 2018 Oct; 52(4):443-450. PubMed ID: 30012440
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
Gu J; Xu J; Zuo TT; Chen YB
J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients.
Hu J; Zha L; Yu YW; Su Q; Fang XL; Ji JR; Shen P; Chen YB; Zheng X; Xiao YH
Int J Antimicrob Agents; 2024 May; 63(5):107152. PubMed ID: 38513747
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa.
Xu C; Zeng F; Huang Y; Xu Q; Yang Y; Gong W; Shi C; Zhang Y
Int J Antimicrob Agents; 2024 Jan; 63(1):107021. PubMed ID: 37890733
[TBL] [Abstract][Full Text] [Related]
8. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection.
Xiao S; Fu Q; Miao Y; Zhao M; Lu S; Xu J; Zhao W
Front Microbiol; 2023; 14():1198926. PubMed ID: 37664109
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant
Chen J; Liang Q; Chen X; Wu J; Wu Y; Teng G; Huang M
Infect Drug Resist; 2022; 15():655-667. PubMed ID: 35241917
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients.
Tsolaki V; Mantzarlis K; Mpakalis A; Malli E; Tsimpoukas F; Tsirogianni A; Papagiannitsis C; Zygoulis P; Papadonta ME; Petinaki E; Makris D; Zakynthinos E
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818820
[TBL] [Abstract][Full Text] [Related]
14. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.
Chen J; Hu Q; Zhou P; Deng S
Infection; 2024 Feb; 52(1):19-28. PubMed ID: 37878197
[TBL] [Abstract][Full Text] [Related]
18. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S; Wang H; Feng S
Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
[TBL] [Abstract][Full Text] [Related]
20. Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis.
Borjan J; Meyer KA; Shields RK; Wenzler E
Int J Antimicrob Agents; 2020 Jan; 55(1):105852. PubMed ID: 31770627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]